# Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

> **NCT02043301** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 75 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **BIOLOGICAL:** Bococizumab (PF-04950615; RN316)
- **BIOLOGICAL:** Bococizumab (PF-04950615; RN316)
- **BIOLOGICAL:** Bococizumab (PF-04950615; RN316)

## Key facts

- **NCT ID:** NCT02043301
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2019-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02043301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02043301, "Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02043301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*